| [17] |
Ott PA, Hu Z, Keskin DB, et al. Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma[J]. Nature, 2018, 555(7696): 402.
|
| [18] |
Roudko V, Greenbaum B, Bhardwaj N. Computational prediction and validation of tumor-associated neoantigens[J]. Front Immunol, 2020, 11: 27.
|
| [19] |
Benedetti R, Dell’Aversana C, Giorgio C, et al. Breast cancer vaccines: new insights[J]. Front Endocrinol (Lausanne), 2017, 8: 270.
|
| [20] |
Singh K, Yadav D, Jain M, et al. Immunotherapy for breast cancer treatment: current evidence and therapeutic options[J]. Endocr Metab Immune Disord Drug Targets, 2022, 22(2): 212-224.
|
| [21] |
Morse MA, Gwin WR, Mitchell DA. Vaccine therapies for cancer: then and now[J]. Target Oncol, 2021, 16(2): 121-152.
|
| [22] |
Corti C, Giachetti PPMB, Eggermont AMM, et al. Therapeutic vaccines for breast cancer: has the time finally come? [J]. Eur J Cancer, 2022, 160: 150-174.
|
| [23] |
Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression[J]. Cancer Res, 2019, 79(18): 4557-4566.
|
| [24] |
Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies[J]. Nat Rev Drug Discov, 2019, 18(3): 197-218.
|
| [25] |
Nagini S. Breast cancer: current molecular therapeutic targets and new players[J]. Anticancer Agents Med Chem, 2017, 17(2): 152-163.
|
| [26] |
Vagia E, Mahalingam D, Cristofanilli M. The landscape of targeted therapies in TNBC[J]. Cancers (Basel), 2020, 12(4): 916.
|
| [27] |
Kufe DW. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene, 2013, 32(9): 1073-1081.
|
| [28] |
Siroy A, Abdul-Karim FW, Miedler J, et al. MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer[J]. Hum Pathol, 2013, 44(10): 2159-2166.
|
| [29] |
Zagorac I, Lončar B, Dmitrović B, et al. Correlation of folate receptor alpha expression with clinicopathological parameters and outcome in triple negative breast cancer[J]. Ann Diagn Pathol, 2020, 48: 151596.
|
| [30] |
Nooka AK, Wang ML, Yee AJ, et al. Assessment of safety and immunogenicity of PVX-410 vaccine with or without lenalidomide in patients with smoldering multiple myeloma: a nonrandomized clinical trial[J]. JAMA Oncol, 2018, 4(12): e183267.
|
| [31] |
Bissanum R, Lirdprapamongkol K, Svasti J, et al. The role of WT1 isoforms in vasculogenic mimicry and metastatic potential of human triple negative breast cancer cells[J]. Biochem Biophys Res Commun, 2017, 494(1-2): 256-262.
|
| [32] |
Zhang Y, Yan WT, Yang ZY, et al. The role of WT1 in breast cancer: clinical implications, biological effects and molecular mechanism[J]. Int J Biol Sci, 2020, 16(8): 1474-1480.
|
| [1] |
Bowen WS, Svrivastava AK, Batra L, et al. Current challenges for cancer vaccine adjuvant development[J]. Expert Rev Vaccines, 2018, 17(3): 207-215.
|
| [2] |
Chiang CL, Kandalaft LE, Coukos G. Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines[J]. Int Rev Immunol, 2011, 30(2-3): 150-182.
|
| [3] |
Adotévi O, Dosset M, Galaine J, et al. Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine[J]. Hum Vaccin Immunother, 2013, 9(5): 1073-1077.
|
| [4] |
Li Q, Li Z, Deng N, et al. Built-in adjuvants for use in vaccines[J]. Eur J Med Chem, 2022, 227: 113917.
|
| [5] |
Karkada M, Berinstein NL, Mansour M. Therapeutic vaccines and cancer: focus on DPX-0907[J]. Biologics, 2014, 8: 27-38.
|
| [6] |
Nezafat N, Ghasemi Y, Javadi G, et al. A novel multi-epitope peptide vaccine against cancer: an in silico approach[J]. J Theor Biol, 2014, 349: 121-134.
|
| [7] |
仲丽晴，刘芹，刘宝瑞. 肿瘤光动力免疫治疗的研究进展[J]. 中华肿瘤防治杂志，2023, 30(6): 341-346.
|
| [8] |
Hutchins LF, Makhoul I, Emanuel PD, et al. Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage Ⅳ breast cancer subjects[J]. Oncotarget, 2017, 8(58): 99 161-99 178.
|
| [9] |
Chen X, Yang J, Wang L, et al. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives[J]. Theranostics, 2020, 10(13): 6011-6023.
|
| [10] |
Sahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy[J]. Science, 2018, 359(6382): 1355-1360.
|
| [11] |
Marron T, Kodysh J, Rubinsteyn A, et al. 289 PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting[J]. J Immunother Cancer, 2020; 8(Suppl 3): A177.
|
| [12] |
Rubinsteyn A, Kodysh J, Hodes I, et al. Computational pipeline for the PGV-001 neoantigen vaccine trial[J]. Front Immunol, 2018, 8: 1807.
|
| [13] |
Marron TU, Saxena M, Bhardwaj N, et al. An adjuvant personalized neoantigen peptide vaccine for the treatment of malignancies (PGV-001) [J]. Cancer Res., 2021，81(13 Suppl)：LB048.
|
| [14] |
Jou J, Harrington KJ, Zocca MB, et al. The changing landscape of therapeutic cancer vaccines-novel platforms and neoantigen identification[J]. Clin Cancer Res, 2021, 27(3): 689-703.
|
| [15] |
贺庆，高华，王军志. 个体化肽治疗性肿瘤疫苗的临床药效学研究分析[J]. 中国新药杂志，2021, 30(19): 1729-1737.
|
| [16] |
Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer[J]. Nature, 2017, 547(7662): 222-226.
|
| [33] |
Zauderer MG, Tsao AS, Dao T, et al. A randomized phase ii trial of adjuvant galinpepimut-s, WT-1 analogue peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma[J]. Clin Cancer Res，2017，23(24)：7483-7489.
|
| [34] |
Jain AG, Talati C, Pinilla-Ibarz J. Galinpepimut-S (GPS): an investigational agent for the treatment of acute myeloid leukemia[J]. Expert Opin Investig Drugs, 2021，30(6)：595-601.
|
| [35] |
McCarthy PM, Clifton GT, Vreeland TJ, et al. AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence[J]. Expert Opin Investig Drugs, 2021, 30(1): 5-11.
|